Skip to main content
. 2015 Feb 17;6(6):4051–4065. doi: 10.18632/oncotarget.3018

Figure 2. The expression of total c-Met, phospho-c-Met, phospho-Erk, and phospho-Akt in cancer cells transduced with c-Met-specific shRNA-expressing Ad.

Figure 2

(A) Various human glioma cancer cell lines were transduced with dl/LacZ, dl/shMet4, dl/shMet5, or dl/shMet4+5 (200 MOI for U251N and U87MG, 100 MOI for U343). c-Met concentration in the culture supernatant was measured at 72 hr after transduction by c-Met ELISA. Data are expressed as the mean ± SE (n = 3), and are representative of at least three independent experiments. (B, C) U343 glioma cells were transduced with dl/LacZ, dl/shMet4, dl/shMet5, or dl/shMet4+5 at 100 MOI. After 3 days, cells were harvested, and the expression levels of total c-Met, phospho-c-Met, phospho-Erk, and phospho-Akt were observed by western blot analysis. Twenty micrograms of protein was loaded in each lane.